Literature DB >> 15218803

Overview of primary progressive multiple sclerosis (PPMS): similarities and differences from other forms of MS, diagnostic criteria, pros and cons of progressive diagnosis.

Alan Thompson1.   

Abstract

Patients with the primary progressive form of multiple sclerosis (PPMS) have a unique clinical course and demonstrate additional demographic and imaging features, which separate them from the relapsing/remitting form of the condition. Whether these features indicate a fundamental difference in the underlying pathogenesis of the condition or simply reflect opposite ends of a clinical spectrum is unclear. What is clear, however, is that this form of MS provides a valuable model of progression, which has the potential to explain this most disabling component of the disease process. The lack of the hallmark relapses and remissions in PPMS poses diagnostic difficulties, some of which have been addressed by recently published diagnostic criteria. Following diagnosis, the need for information, specific to this form of MS, must be recognized and addressed.

Entities:  

Mesh:

Year:  2004        PMID: 15218803     DOI: 10.1191/1352458504ms1024oa

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  13 in total

1.  Exploring the relationship between white matter and gray matter damage in early primary progressive multiple sclerosis: an in vivo study with TBSS and VBM.

Authors:  Benedetta Bodini; Zhaleh Khaleeli; Mara Cercignani; David H Miller; Alan J Thompson; Olga Ciccarelli
Journal:  Hum Brain Mapp       Date:  2009-09       Impact factor: 5.038

2.  Meeting the needs of people with primary progressive multiple sclerosis, their families, and the health-care community.

Authors:  Nancy J Holland; Diana M Schneider; Robert Rapp; Rosalind C Kalb
Journal:  Int J MS Care       Date:  2011

Review 3.  The importance of studying sex differences in disease: The example of multiple sclerosis.

Authors:  Lisa C Golden; Rhonda Voskuhl
Journal:  J Neurosci Res       Date:  2017-01-02       Impact factor: 4.164

4.  Sex chromosome contributions to sex differences in multiple sclerosis susceptibility and progression.

Authors:  Rhonda R Voskuhl; Amr H Sawalha; Yuichiro Itoh
Journal:  Mult Scler       Date:  2018-01       Impact factor: 6.312

5.  Multiple sclerosis with a progressive course from onset in Lorraine-Eastern France.

Authors:  M Debouverie; S Louis; S Pittion-Vouyovitch; T Roederer; H Vespignani
Journal:  J Neurol       Date:  2007-06-25       Impact factor: 4.849

6.  Characterization of functioning in multiple sclerosis using the ICF.

Authors:  Lisa Holper; Michaela Coenen; Andrea Weise; Gerold Stucki; Alarcos Cieza; Jürg Kesselring
Journal:  J Neurol       Date:  2010-01       Impact factor: 4.849

7.  Grey matter damage in progressive multiple sclerosis versus amyotrophic lateral sclerosis: a voxel-based morphometry MRI study.

Authors:  Eleonora Tavazzi; Maria Marcella Laganà; Niels Bergsland; Paola Tortorella; Giovanna Pinardi; Christian Lunetta; Massimo Corbo; Marco Rovaris
Journal:  Neurol Sci       Date:  2014-09-17       Impact factor: 3.307

8.  Progressive Onset Multiple Sclerosis: Demographic, Clinical and Laboratory Characteristics of Patients With and Without Relapses in the Course.

Authors:  Bahar Kaymakamzade; Ahmet Kasım Kiliç; Aslı Tuncer Kurne; Rana Karabudak
Journal:  Noro Psikiyatr Ars       Date:  2018-07-04       Impact factor: 1.339

9.  Magnetisation transfer ratio in the normal appearing white matter predicts progression of disability over 1 year in early primary progressive multiple sclerosis.

Authors:  Z Khaleeli; J Sastre-Garriga; O Ciccarelli; D H Miller; A J Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-02-07       Impact factor: 10.154

10.  A novel data mining system points out hidden relationships between immunological markers in multiple sclerosis.

Authors:  Maira Gironi; Marina Saresella; Marco Rovaris; Matilde Vaghi; Raffaello Nemni; Mario Clerici; Enzo Grossi
Journal:  Immun Ageing       Date:  2013-01-10       Impact factor: 6.400

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.